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Abstract
Background: Studies examining the association of apolipoprotein A5 (APOA5) gene -1131 T>C polymorphism with
blood lipids produced inconsistent results. In this meta-analysis encompassing all the relevant studies, we aimed to
investigate the association of the -1131 T>C polymorphism with fasting blood lipids.
Methods: We limited our analysis to the following four blood lipid variables: total cholesterol (TC), triglycerides
(TG), low density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). Subjects were
confined to adults who were at least 18 years old. A dominant model was used for this meta-analysis. 37 studies
with 37859 subjects were included in this meta-analysis.
Results: The results showed that the carriers of -1131C allele have higher blood TC and TG than the non-carriers:
standardized mean difference (SMD) = 0.08, 95% confidence interval (CI, 0.05, 0.11), P < 0.00001, Pheterogeneity = 0.42,
and SMD = 0.31, 95% CI (0.27, 0.34), P < 0.00001, Pheterogeneity = 0.0003, respectively. Significant association between
the -1131 T>C polymorphism and lower blood HDL-C was also detected under the dominant model: SMD = -0.17,
95% CI (-0.21, -0.14), P < 0.00001, Pheterogeneity = 0.003.
Conclusions: Our meta-analysis supports the strong association of the APOA5 -1131 T>C polymorphism with
higher levels of TC and TG, and lower levels of HDL-C.
Background
Hyperlipidemia, which is considered to be one of the
most important risk factors for coronary heart disease
(CHD) and stroke, is characterized by the derangements
of one or many of the lipids: elevations of total choles-
terol (TC), low density lipoprotein cholesterol (LDL-C)
and/or triglycerides (TG), or low levels of high-density
lipoprotein cholesterol (HDL-C) [1]. Although a large
number of studies have tried to elucidate the pathogen-
esis of the disease, the exact underlying mechanisms are
still not completely understood [2]. In recent years,
much has been learned about specific genes that influ-
ence hyperlipidemia [3]. However, due to various rea-
sons, including considerable heterogeneity of the
disease, the identification of susceptibility genes is diffi-
cult and most associations have not been replicated [3].
More recently, apolipoprotein A5 (APOA5) was iden-
tified as a strong modulator of blood lipids [4]. The
APOA5 is predominantly synthesized in the liver and
secreted into the plasma where it plays a central role in
regulating TG metabolism [4]. A higher plasma APOA5
would result in lower TG levels [5]. APOA5 knockout
mice develop hypertriglyceridemia, whereas transgenic
mice overexpressing APOA5 have low TG levels [5].
APOA5 reduces plasma TG by inhibiting very low den-
sity lipoprotein-TG production and stimulating lipopro-
tein lipase-mediated very low density lipoprotein-TG
hydrolysis [6]. APOA5 also play important roles in mod-
ulating other blood lipid metabolism [6-8]. Several stu-
dies have demonstrated that the APOA5 gene
polymorphisms are associated with reduced HDL-C
levels and decreased low density lipoprotein particle size
[6-10]. Given its role in blood lipid metabolism, the
APOA5 gene is considered a candidate gene for
hyperlipidemia.
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The APOA5 gene is located on chromosome 11q23
within the APOA1/C3/A4/A5 gene cluster, and com-
prises 4 exons encoding 366 amino acids [5,11]. A num-
ber of human APOA5 gene nucleotide polymorphisms
(SNPs) have been investigated for a possible role in med-
iating genetic predisposition to hyperlipidemia [11]. The
most extensively studied polymorphism is APOA5 -
1131 T>C polymorphism (rs662799, SNP3). This poly-
morphism is located in the promoter region of the
APOA5 gene [12]. A number of investigators studied the
possible association between this polymorphism and
blood lipids, but the results are conflicting and inconclu-
sive [6-42]. In this paper, a meta-analysis was performed
on previous reports to investigate the association of the
APOA5 -1131 T>C polymorphism with fasting blood
lipids.
Methods
Identification and eligibility of relevant studies
We identified all articles published before November
2009 on the APOA5 -1131 T>C polymorphism and its
association with blood lipids. A systematic search of the
literature was carried out by using PubMed and HugeN-
avigator. The language was limited to English. The key-
words used for this search were “APOAV OR APOA-V
OR apolipoprotein A-V OR apolipoprotein AV OR apo-
lipoprotein A5 OR APOA5 OR APO A5” concatenated
with “polymorphism OR variant OR SNP OR mutation”.
We limited our analysis to the following four blood lipid
variables: TC, TG, LDL-C, and HDL-C. The selection
criteria for studies to be considered for this meta-analy-
sis were as follows: (1) data were reported on at least 1
of the four blood lipid variables; (2) data reported on
fasting blood lipid; (3) in case of interventional studies,
we used pre-intervention baseline data; (4) we only
included studies in which mean blood lipid levels and
standard deviations (SD) or standard errors by genotype
were available; (5) subjects were confined to adults who
were at least 18 years old. All references cited in the
studies were also reviewed in order to find other pub-
lished work that was not indexed by PubMed and
HugeNavigator. Animal studies, case reports, review
articles, abstracts, reports with incomplete data, and stu-
dies based on pedigree data were excluded.
Data extraction
Two investigators independently reviewed the articles to
exclude irrelevant and overlapping studies. The results
were compared, and disagreements were discussed and
resolved by consensus. When overlapping articles were
found, we only included the publication that reported the
most extensive information. From each study, the follow-
ing information was extracted: journal, year of publica-
tion, first author, demographics, racial background of the
study population, fasting status, age, sex, health condition,
sample size, mean and SD or standard error by geno-
types, genotyping and lipid assay methods, unit of the
four lipid variables.
Statistical analysis
All data in this analysis were presented as mean ± SD.
When the standard error was reported in the original
article, the value of the SD was calculated. Review Man-
ager 5.0 software (The Cochrane Collaboration, Oxford,
UK) was used for the meta-analysis. Because the fre-
quencies of the minor allele homozygous were low, to
ensure adequate statistical power, we employed a domi-
nant model [(TC+CC) versus TT] for this meta-analysis.
When information was reported for more than one sub-
population (for example, male subjects or female sub-
jects, subjects with type 2 diabetes and control subjects,
subjects from different geographical areas or different
ethnicity) in one study, each subpopulation was treated
as a separate comparison in our meta-analysis. In addi-
tion, we conducted subgroup analyses by ethnicity, gen-
der, and health condition. Ethnic subgroups were
defined as European descendents, East Asian, or popula-
tions of other ethnic origins. Considering that the effects
of APOA 5 gene on blood lipids may be influenced by
lipid-lowering therapy, we also performed a subgroup
analysis in subjects without taking lipid-lowering medi-
cation. The healthy subjects (normal subjects or healthy
subjects) and the subjects who ceased lipid-lowering
therapy at least 1 month were also included in this sub-
group. For TG, we also conducted a larger study (with
sample size more than five hundreds) subgroup analysis.
To ensure adequate statistical power, we only performed
the meta-analysis on the subgroup with at least four
studies.
The existence of heterogeneity between studies was
ascertained by Q-statistic. Heterogeneity was considered
significant for P < 0.1. A pooled standardized mean dif-
ference (SMD), together with 95% confidence interval
(CI), was used for this meta-analysis. The SMD was
chosen because the blood lipids were measured using
different scanners [43]. Because a random effects model
considers both between-study and within-study hetero-
geneity, it provides a more conservative evaluation of
the significance of the association than one based on
fixed effects [44]. The random effects model was used
for this meta-analysis.
All populations described in the studies were tested
for Hardy-Weinberg equilibrium (HWE). We repeatedly
performed the meta-analysis via excluding the studies
not in HWE to test the stability of the results.
Galbraith plot, made by MIX 1.7 software (Kitasato
Clinical Research Center, Kitasato University, Japan),
was used to detect potential sources of heterogeneity
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[45,46]. The pooled SMDs were recalculated after
removal of the outlier studies identified in the plot.
Funnel plot was performed to look for evidence of pub-
lication bias. The funnel plot should be asymmetric when
there is publication bias and symmetric in case of no
publication bias. Egger’s test, estimated by MIX 1.7 soft-
ware was performed to measure the funnel plot asymme-
try [45-47]. A significance level of 0.1 was used as an
indication for the presence of potential publication bias.
A P < 0.1 indicates the presence of publication bias.
Results
Selection and characteristics of studies
Additional file 1 (figure legend of additional file 1 is in
additional file 2) describes the flow of candidate and eli-
gible papers. Initial search of the literature yielded 220
publications. We excluded 91 irrelevant papers on the
basis of title and abstract. The original papers were
retrieved and evaluated for compliance with the inclu-
sion criteria. 92 papers were ineligible for the following
reasons: 43 papers did not provide complete data for
this meta-analysis, 29 papers presented data on other
polymorphisms, 8 papers had subjects overlap with
other publications, 6 studies were based on pedigree
data, 5 papers were review articles, and 1 paper involved
subjects younger than 18 years.
The selected study characteristics were summarized in
Table S1 of additional file 3. A total of 37 studies were
included in this meta-analysis. Of these, 34, 27, 23, and
30 studies separately presented the data on TG, TC,
LDL-C, and HDL-C. In the 37 studies, there were 13
studies of European descendents, 15 studies of East
Asians, 5 studies of other ethnic origins. 4 studies
reported results on different racial descendent popula-
tion and each population was treated as a separate com-
parison in the meta-analysis. In 1 study, all the subjects
were female, and in 5 studies, all the subjects were male;
while in the remaining 31 studies, the subjects consisted
of both male and female; among the 31 studies, 4 stu-
dies provided the data on male and female subjects
respectively. In the eligible studies, 6 studies involved
subjects with type 2 diabetes, 9 studies involved healthy
subjects, and 6 studies involved subjects with CHD. 19
studies clearly stated that the overall populations or
one/several subpopulations did not take lipid-lowering
medication. In all 37 studies, there were 19 studies sepa-
rately providing the information on more than one sub-
population. Each subpopulation was treated as a
separate comparison. Genotype distribution in 3 subpo-
pulations from 3 studies significantly deviated from the
expected HWE. The units of blood lipids used in the eli-
gible studies included mg/dl and mmol/L. The complete
blood lipids data by genotypes can be found in Table S2
of additional file 3.
Summary statistics
We distinguished 66 comparisons on the basis of cate-
gories like ethnicity, gender, and health condition. Of
these, 60, 42, 37, and 48 comparisons were included for
comparing the difference in blood TG, TC, LDL-C, and
HDL-C, respectively (Table S2 of additional file 3, Table
1). Overall, 37859 subjects were enrolled in this meta-
analysis. Among them, 24226 subjects (64%) had the
genotype TT, and 13633 (36%) were carriers of -1131C
allele (Table S2 of additional file 3). 34193, 20961,
19860, and 29588 subjects were included in comparing
the difference in blood TG, TC, LDL-C, and HDL-C,
respectively (Table S2 of additional file 3).
C polymorphism and
TC",1,0,1,0,0pc,0pc,0pc,0pc>Association between the
APOA5 -1131 T>C polymorphism and TC
We first performed the meta-analysis on all 42 compari-
sons. The result showed that the carriers of -1131C
allele have higher blood TC than the non-carriers: SMD
= 0.08, 95% CI (0.05, 0.11), P < 0.00001, Pheterogeneity =
0.42 (Table 1, Figure 1). We then performed the sub-
group analyses stratified by the characteristics of the
subjects. The significant association between the
APOA5 -1131 T>C polymorphism and blood TC in
subjects without taking lipid-lowering medication was
also detected under the dominant models: SMD = 0.08,
95% CI (0.03, 0.14), P = 0.003, Pheterogeneity = 0.47 (Table
1). The association between the APOA5 -1131 T>C
polymorphism and higher levels of TC under dominant
model was significant in East Asians, and marginally sig-
nificant in European descendents: SMD = 0.09, 95% CI
(0.05, 0.13), P < 0.0001, Pheterogeneity = 0.69, and SMD =
0.07, 95% CI (-0.00, 0.15), P = 0.05, respectively (Table
1). The other pooled SMDs from the subgroup analyses
were not significant (P>0.05) (Table 1).
We next conducted the analyses excluding the studies
not in HWE (Table 1). The association between the
APOA5 -1131 T>C polymorphism and higher levels of
TC under dominant model was not significant in Eur-
opean descendents: SMD = 0.07, 95% CI (-0.02, 0.16), P
= 0.11, Pheterogeneity = 0.09. The other results were simi-




APOA5 -1131 T>C polymorphism and TG
The result from the meta-analysis on all 60 comparisons
showed that the carriers of -1131C allele have higher
blood TG than the non-carriers in overall population:
SMD = 0.31, 95% CI (0.27, 0.34), P < 0.00001, Phetero-
geneity = 0.0003 (Table 1, Figure 2). The association
between the APOA5 -1131 T>C polymorphism and
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Table 1 Meta-analysis of the APOA5 -1131T>C polymorphism and blood lipids association
Group and subgroups under analysis Comparisons (n) Q test P value SMD (95% CI) P
TC
All 42 0.42 0.08 (0.05, 0.11) <0.00001
All in HWE 39 0.30 0.08 (0.04, 0.12) 0.0001
No lipid-lowering medicine 20 0.47 0.08 (0.03, 0.14) 0.003
No lipid-lowering medicine in HWE 19 0.41 0.08 (0.02, 0.14) 0.005
European 16 0.16 0.07 (-0.00, 0.15) 0.05
European in HWE 14 0.09 0.07 (-0.02, 0.16) 0.11
East Asian 18 0.69 0.09 (0.05, 0.13) <0.0001
East Asian in HWE 17 0.63 0.09 (0.04, 0.15) 0.0003
Other 8 0.45 0.04 (-0.03, 0.11) 0.23
Healthy 8 0.45 0.04 (-0.04, 0.13) 0.31
Type 2 diabetes 7 0.64 0.11 (-0.01, 0.23) 0.07
CHD 6 0.71 0.06 (-0.03, 0.15) 0.18
CHD in HWE 5 0.58 0.06 (-0.04, 0.15) 0.22
Male 6 0.29 0.02 (-0.09, 0.13) 0.67
Male in HWE 5 0.20 0.03 (-0.12, 0.17) 0.74
TG
All 60 0.0003 0.31 (0.27, 0.34) <0.00001
All in HWE 58 0.004 0.31 (0.28, 0.35) <0.00001
No lipid-lowering medicine 28 0.35 0.33 (0.29, 0.38) <0.00001
No lipid-lowering medicine in HWE 27 0.32 0.33 (0.29, 0.38) <0.00001
European 21 0.29 0.36 (0.29, 0.43) <0.00001
European in HWE 20 0.26 0.36 (0.29, 0.43) <0.00001
East Asian 23 0.001 0.34 (0.29, 0.39) <0.00001
East Asian in HWE 22 0.10 0.35 (0.30, 0.39) <0.00001
Other 16 0.27 0.21 (0.16, 0.26) <0.00001
Healthy 8 0.89 0.36 (0.27, 0.44) <0.00001
Type 2 diabetes 7 0.77 0.40 (0.29, 0.52) <0.00001
CHD 6 0.88 0.39 (0.29, 0.48) <0.00001
CHD in HWE 5 0.81 0.38 (0.28, 0.48) <0.00001
Male 10 0.39 0.26 (0.19, 0.33) <0.00001
Female 7 0.13 0.21 (0.11, 0.31) <0.0001
Larger 25 0.009 0.26 (0.22, 0.30) <0.00001
Larger in HWE 24 0.05 0.27 (0.23, 0.31) <0.00001
LDL-C
All 37 0.010 0.03 (-0.02, 0.07) 0.22
All in HWE 34 0.009 0.02 (-0.02, 0.07) 0.34
No lipid-lowering medicine 16 0.32 0.02 (-0.05, 0.08) 0.61
No lipid-lowering medicine in HWE 15 0.26 0.02 (-0.05, 0.09) 0.58
European 11 0.01 -0.00 (-0.10, 0.10) 0.99
European in HWE 9 0.005 -0.01 (-0.14, 0.12) 0.93
East Asian 20 0.04 0.04 (-0.01, 0.10) 0.14
East Asian in HWE 19 0.05 0.04 (-0.03, 0.10) 0.25
Other 6 0.44 0.02 (-0.06, 0.09) 0.68
Healthy 8 0.03 0.05 (-0.09, 0.18) 0.50
Type 2 diabetes 8 0.11 0.04 (-0.09, 0.16) 0.55
CHD 5 0.73 -0.03 (-0.12, 0.07) 0.55
CHD in HWE 4 0.57 -0.03 (-0.13, 0.07) 0.56
Male 5 0.02 -0.06 (-0.25, 0.13) 0.51
Male in HWE 4 0.02 -0.09 (-0.34, 0.15) 0.47
HDL-C
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higher levels of TG under dominant model was also sig-
nificant across all subpopulations (P < 0.0001) (Table 1).
There was significant heterogeneity among the avail-
able studies. However, the heterogeneity was effectively
decreased or removed in the subgroups stratified by the
characteristics of the subjects (Table 1).
C polymorphism and LDL-
C",1,0,1,0,0pc,0pc,0pc,0pc>Association between the
APOA5 -1131 T>C polymorphism and LDL-C
The results from our meta-analysis did not suggest a
significant association between the -1131 C>T poly-
morphism and higher levels of LDL-C under dominant
model (P>0.05) (Table 1, Table 2, Figure 3).
There was significant heterogeneity among the avail-
able studies. Significant heterogeneity was also observed
in European subgroup, East Asian subgroup, healthy
subject subgroup, and male subject subgroup (Table 1).
3 studies (Alberle, 2005, Baum 1, 2007, and Li 2, 2008)
were identified as the main contributors of heterogeneity
by using the Galbraith plot [Table S1 of additional file 3,
additional file 4A (Figure legend is in additional file 2)]
[20,35]. The heterogeneity was effectively removed
or decreased after exclusion of these outlier studies
(Table 2).
C polymorphism and HDL-
C",1,0,1,0,0pc,0pc,0pc,0pc>Association between the
APOA5 -1131 T>C polymorphism and HDL-C
We first performed the meta-analysis on all 48 compari-
sons. The result showed that the carriers of -1131C
allele have lower blood HDL-C than the non-carriers:
SMD = -0.17, 95% CI (-0.21, -0.14), P < 0.00001, Phetero-
geneity = 0.003 (Table 1, Figure 4). We then performed
the subgroup analyses stratified by the characteristics of
the subjects. All findings from these analyses were
Table 1 Meta-analysis of the APOA5 -1131T>C polymorphism and blood lipids association (Continued)
All 48 0.003 -0.17 (-0.21, -0.14) <0.00001
All in HWE 45 0.003 -0.17 (-0.21, -0.14) <0.00001
No lipid-lowering medicine 24 0.003 -0.20 (-0.27, -0.13) <0.00001
No lipid-lowering medicine in HWE 23 0.002 -0.20 (-0.28, -0.13) <0.00001
European 13 0.03 -0.15 (-0.24, -0.06) 0.002
European in HWE 11 0.01 -0.16 (-0.27, -0.05) 0.006
East Asian 25 0.07 -0.20 (-0.24, -0.16) <0.00001
East Asian in HWE 24 0.07 -0.19 (-0.24, -0.15) <0.00001
Other 10 0.13 -0.14 (-0.22, -0.06) 0.0008
Healthy 8 0.29 -0.17 (-0.26, -0.07) 0.0007
Type 2 diabetes 9 0.36 -0.18 (-0.28, -0.09) 0.0002
CHD 5 0.003 -0.21 (-0.42, -0.01) 0.06
CHD in HWE 4 0.002 -0.24 (-0.48, -0.01) 0.06
Male 6 0.55 -0.11 (-0.20, -0.02) 0.02
Male in HWE 5 0.41 -0.11 (-0.21, -0.00) 0.05
Figure 1 Forest plot of the APOA5 -1131 T>C polymorphism
and TC association. Result from the analysis on all 42 comparisons.
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significant (P < 0.05) except that the association between
the APOA5 -1131 T>C polymorphism and lower blood
HDL-C under dominant model was marginally
significant in CHD subjects: SMD = -0.21, 95% CI
(-0.42, -0.01), P = 0.06, Pheterogeneity = 0.003 (Table 1).
We next conducted the analyses excluding the studies
not in HWE (Table 1). The association between the
APOA5 -1131 T>C polymorphism and lower levels of
HDL-C under dominant model was marginally significant
in male subjects: SMD = -0.11, 95% CI (-0.21, -0.00),
P = 0.05, Pheterogeneity = 0.41. The remaining results from
these analyses were similar to those when the studies not
in HWE were included.
There was significant heterogeneity among the avail-
able studies. Significant heterogeneity was also observed
in European subgroup, East Asian subgroup, subgroup
of subjects with CHD, and subgroup of subjects without
taking lipid-lowering medicine (Table 1). 4 studies
(Kisfali 1, 2009, Komurcu-Bayrak 1, 2008, Liu 2, 2005,
and Yamada 2, 2007) were identified as the main contri-
butors of heterogeneity by using the Galbraith plot
[Table S1 of additional file 3, additional file 4B (Figure
legend is in additional file 2)] [20,35]. The heterogeneity
was effectively removed or decreased after exclusion of
these outlier studies (Table 2). The association between
the APOA5 -1131 T>C polymorphism and lower blood
HDL-C under dominant model was significant in CHD
subjects: for the analysis including all studies on subjects
with CHD: SMD = -0.12, 95% CI (-0.23, -0.01), P = 0.04,
Pheterogeneity = 0.61, and for the analysis excluding the
studies not in HWE: SMD = -0.12, 95% CI (-0.24,
-0.01), P = 0.04, Pheterogeneity = 0.42 (Table 2). The other
results from these analyses were similar to those when
the outlier studies were included (Table 2, Figure 4).
Publication bias
Publication bias was assayed by visual funnel plot
inspection and Egger’s test. The funnel plots comparing
the differences in TC, LDL-C, and HDL-C were all basi-
cally symmetric [Additional file 5A, 5B, 5C (Figure
legend is in additional file 2)] and Egger’s test did not
indicate asymmetry of the plots: Intercept = -0.1374,
95% CI (-0.9238, 0.6491), P = 0.7259, Intercept
= -0.2542, 95% CI (-1.397, 0.8886), P = 0.6544, and
Intercept = 0.0825, 95% CI (-0.7668, 0.9319), P =
0.8458, respectively. The funnel plot comparing the dif-
ference in TG showed asymmetry that suggested the
existence of publication bias [Additional file 5D (Figure
legend is in additional file 2)], and Egger’s test did not
indicate symmetry of the plots: Intercept = 1.0584, 95%
CI (0.3716, 1.7451), P = 0.0031. To further evaluate the
relationship between the APOA5 -1131 T>C poly-
morphism and blood TG, we carried the subgroup ana-
lysis only including the studies with sample size more
than five hundreds. The funnel plot for these studies
was basically symmetric [Additional file 5E (Figure
legend is in additional file 2)] and Egger’s test did not
indicate asymmetry of the plot: Intercept = -0.0596, 95%
CI (-1.7364, 1.6173), P = 0.9421.
Discussion
The APOA5 -1131 T>C polymorphism has been sug-
gested as a possible genetic factor associated with hyper-
lipidemia [4,5]. However, the results from the published
Figure 2 Forest plot of the APOA5 -1131 T>C polymorphism
and TG association. Result from the analysis on all 60 comparisons.
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studies on the association of this polymorphism with
hyperlipidemia are conflicting and inconclusive [6-42].
The lack of concordance across many of these studies
reflects limitation in the studies, such as small sample
sizes, ethnic difference and research methodology.
In this meta-analysis, we investigated the association
of the APOA5 -1131 T>C polymorphism with fasting
blood lipids. Because the frequencies of the minor allele
homozygous were low, most of the studies included in
this meta-analysis only provided mean blood lipid levels
of all allele C carriers and did not respectively provide
mean blood lipid levels of homozygote CC and hetero-
zygote CT. To ensure adequate statistical power, we
employed a dominant model for this meta-analysis. The
results suggest that the APOA5 -1131 T>C polymorph-
ism under dominant model is significantly associated
with fasting blood lipids. The carriers of -1131C allele
have higher levels of TC and TG, and lower levels of
HDL-C than the non-carriers. In the eligible studies,
some studies clearly stated that the overall populations
or one/several subpopulations did not take lipid-lower-
ing medication. Because the effects of APOA5 gene on
blood lipids may be influenced by lipid-lowering ther-
apy, we performed the subgroup analyses in subjects
without taking lipid-lowering medication. The similar
association between the -1131 T>C polymorphism and
the three blood lipid variables was also detected in these
subjects. Since gender, ethnicity, and health condition
probably were important variables in determining asso-
ciative risk with hyperlipidemia, we performed subgroup
analyses of gender, ethnicity, and health condition. The
effect of this polymorphism on TC especially exists in
East Asians, and the effect on TG exists in all subpopu-
lations included in this meta-analysis. For the associa-
tion of the -1131 T>C polymorphism with lower levels
of HDL-C, all findings from this meta-analysis were sig-
nificant except that the association was marginally sig-
nificant in male subjects. More studies should be
conducted to further examine the association of this
polymorphism with HDL-C in male subjects. The asso-
ciation of the -1131 T>C polymorphism with blood
HDL-C, TG, and TC was very robust, which did not
vary materially when the analyses that removed the stu-
dies not in HWE were performed. The significant asso-
ciation of the APOA5 -1131 T>C polymorphism with
blood HDL-C was also supported by the results from
the meta-analysis performed after removal of the outlier
studies. However, our meta-analysis does not suggest
Table 2 Meta-analysis of the APOA5 -1131T>C polymorphism and blood lipids association (excluding the outlier
studies)
Group and subgroups under analysis Comparisons (n) Q test P value SMD (95% CI) P
LDL-C
All 34 0.28 0.03 (-0.01, 0.06) 0.12
All in HWE 31 0.28 0.02 (-0.02, 0.06) 0.34
No lipid-lowering medicine 15 0.76 -0.00 (-0.06, 0.06) 0.94
No lipid-lowering medicine in HWE 14 0.69 -0.00 (-0.06, 0.06) 0.96
European 10 0.26 0.05 (-0.04, 0.13) 0.27
European in HWE 8 0.14 0.05 (-0.06, 0.16) 0.38
East Asian 18 0.24 0.02 (-0.03, 0.07) 0.37
East Asian in HWE 17 0.40 0.00 (-0.05, 0.06) 0.87
Healthy 7 0.18 -0.00 (-0.11, 0.11) 0.98
Type 2 diabetes 7 0.36 -0.01 (-0.11, 0.10) 0.89
Male 4 0.14 0.01 (-0.17, 0.19) 0.94
Male in HWE 3 0.07 -0.01 (-0.30, 0.29) 0.96
HDL-C
All 44 0.55 -0.15 (-0.18, -0.13) <0.00001
All in HWE 41 0.66 -0.15 (-0.17, -0.12) <0.00001
No lipid-lowering medicine 21 0.66 -0.15 (-0.20, -0.10 <0.00001
No lipid-lowering medicine in HWE 20 0.61 -0.15 (-0.20, -0.10) <0.00001
European 12 0.46 -0.11 (-0.17, -0.05) 0.0005
European in HWE 10 0.29 -0.12 (-0.20, -0.04) 0.005
East Asian 23 0.71 -0.18 (-0.21, -0.15) <0.00001
East Asian in HWE 22 0.80 -0.17 (-0.20, -0.13) <0.00001
Other 9 0.74 -0.10 (-0.16, -0.03) 0.004
CHD 4 0.61 -0.12 (-0.23, -0.01) 0.04
CHD in HWE 3 0.42 -0.12 (-0.24, -0.01) 0.04
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the significant association of the APOA5 -1131 T>C
polymorphism with blood LDL-C under dominant
model. Genome-wide association studies have suggested
that the polymorphisms in or near the APOA5 gene are
among the strongest known genetic determinants of tri-
glyceride concentration [48,49]. Our findings also are
consistent the results from a meta-analysis by Triglycer-
ide Coronary Disease Genetics Consortium and Emer-
ging Risk Factors Collaboration, in which they reported
that the APOA5 -1131 T>C polymorphism is associated
with increased blood TG and lower HDL-C, and is not
associated with increased LDL-C [50]. The different
effects of the -1131 T>C polymorphism on TC, TG,
HDL-C, and LDL-C suggest that pathogenesis may dif-
ferent in different lipid fractions and the -1131 T>C
polymorphism may exert varying effect.
Significant heterogeneity was respectively found across
the studies for TG, LDL-C, and HDL-C. Prominent
sources of heterogeneity include: differences in ancestry,
different study design, gender difference, and healthy
status of the subjects included in the meta-analysis, etc.
To explore the potential source of the observed hetero-
geneity, we performed subgroup analyses stratified by
the characteristics of the subjects. For TG, the heteroge-
neity was effectively decreased or removed in the sub-
group analyses. For LDL-C and HDL-C, significant
heterogeneity was still observed in some subgroups. The
sources of heterogeneity were further evaluated by Gal-
braith plot. Outlier studies were identified as the main
contributors of heterogeneity by using the plot. The het-
erogeneity was effectively removed or decreased after
exclusion of these outlier studies.
Figure 3 Forest plot of the APOA5 -1131 T>C polymorphism and LDL-C association. Result from the analysis on all 37 comparisons. There
was significant heterogeneity among the studies. The pooled SMD was recalculated after removal of the outlier studies.
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Significant publication bias was present in the studies
on TG. Any meta-analysis carries the risk of publication
bias caused by the fact that small studies with positive
results are more likely to be published than those with
negative results [51]. Therefore, a meta-analysis of larger
studies will generally yield more conservative results
than a meta-analysis of all published studies [51]. To
further evaluate the relationship between the APOA5
-1131 T>C polymorphism and blood TG, we carried
subgroup analysis only including the studies with sample
size more than five hundreds. There was no evidence of
publication bias for this subgroup analysis. The results
from this analysis also suggest a significant association
of the -1131 T>C polymorphism with lower levels of
TG.
The association of the APOA5 -1131 T>C polymorph-
ism with blood TC, TG, and HDL-C is not likely to be
due to type I errors (false-positive results). First, the ran-
dom effects model was used in our meta-analysis.
Because the random effects model provides a more con-
servative evaluation of the significance of the association
than one based on fixed effects, the results from our
Figure 4 Forest plot of the APOA5 -1131 T>C polymorphism and HDL-C association. Result from the analysis on all 48 comparisons. There
was significant heterogeneity among the studies. The pooled SMD was recalculated after removal of the outlier studies.
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meta-analysis are based on a more conservative evalua-
tion, which was expected to avoid false-positive results.
Second, 37 studies with 37859 subjects were included in
this meta-analysis. Among the subjects, 36% of them
were carriers of -1131C allele. If the incidence of the
Thr 54 carriers was sufficiently high, this may have pre-
vented the type I error.
The possible mechanism by which -1131 T>C poly-
morphism modulates lipids metabolism has not yet been
investigated in detail. Study has shown that APOA5
knockout mice develop hypertriglyceridemia, whereas
transgenic mice overexpressing APOA5 have low trigly-
ceride levels [5]. Since the -1131 T>C polymorphism is
located within the promoter region of the APOA5 gene
and might potentially result in a decreased rate of
APOA5 mRNA translation, which could lead to lower
plasma APOA5 levels, and then cause to higher levels of
TG [32]. It is well known that plasma levels of TG and
HDL-C are inversely related. A higher blood TG com-
monly associates with a lower blood HDL-C. A hypoth-
esis for this association is that the delayed TG
hydrolysis, due APOA5 deficiency, reduces the availabil-
ity of surface components of TG-rich lipoproteins
(which contribute to HDL-C formation), thereby leading
to a decreased formation of HDL-C [52]. Another
hypothesis for the association of the APOA5 -1131 T>C
polymorphism with lower HDL-C is that the absence of
APOA5, which is a minor protein component of HDL-
C, renders HDL-C more unstable and more easily
removed from the circulation [52]. Our meta-analysis
also suggests the significant association of the -1131
T>C polymorphism with lower TC. It is more likely that
the -1131 T>C polymorphism is in linkage disequili-
brium with other causative mutations or nearby genes
involved in the metabolism of TC [19]. APOA5 gene
was identified as part of the APOA1/C3/A4/A5 gene
cluster which is key components in modulating lipid
metabolism [5,11]. Several SNPs in the APOA1/C3/A4/
A5 gene cluster have been reported to significantly
affect blood lipid levels [23,24]. Studies have reported
linkage disequilibrium of the -1131 T>C polymorphism
with other variants located in the APOA1/C3/A4/A5
gene cluster [19].
The current meta-analysis has several limitations which
should be noted. First, hyperlipidemia originates from the
interactions of multiple genes, environmental factors, and
behavior. Lacking of the original data of the included
studies limited our further evaluation of potential
interactions because the interactions among gene-gene,
gene-environment and even different polymorphic loci of
the same gene may modulate blood lipid levels. For
example, we did not perform the stratification analyses
by environmental factors such as diet, exercise, and
smoking. A more precise analysis could be conducted if
more detailed individual data were available, which
would allow for an adjusted estimate. Second, we did not
perform a meta-analysis for haplotype analysis of the
APOA5 gene, because a very limited number of studies
were available. Third, for LDL-C, a relative small number
of subjects were included in this meta-analysis, which
may lead to lower statistic power and type II errors
(false- negative results). More studies with larger popula-
tion will be required to further examine the association.
Fourth, because it was very difficult to get the full papers
published in various languages, we only included the stu-
dies published in English. Thus the limitations mentioned
may affect our final conclusions.
Conclusions
In conclusion, our meta-analysis supports the strong
association of the APOA5 -1131 T>C polymorphism
with higher levels of TC and TG, and lower levels of
HDL-C.
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